Chronic immune checkpoint inhibitor pneumonitis
Chronic immune checkpoint inhibitor pneumonitis
About this item
Full title
Author / Creator
Naidoo, Jarushka , Cottrell, Tricia R , Lipson, Evan J , Forde, Patrick M , Illei, Peter B , Yarmus, Lonny B , Voong, K Ranh , Feller-Kopman, David , Lee, Hans , Riemer, Joanne , Wang, Daphne , Taube, Janis M , Brahmer, Julie R , Lin, Cheng Ting , Danoff, Sonye K , D'Alessio, Franco R and Suresh, Karthik
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundPneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks of corticosteroid therapy. Herein, we report the incidence, clinicopathological features and man...
Alternative Titles
Full title
Chronic immune checkpoint inhibitor pneumonitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_244175d2173e40ba8ff2075dd57c06fb
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_244175d2173e40ba8ff2075dd57c06fb
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2020-000840
